XML 61 R40.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration Agreements (Ipsen Collaboration) (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | ---
Dec. 31, 2016 USD ($) | Nov. 30, 2016 USD ($) | Mar. 31, 2016 USD ($) | Jun. 30, 2017 USD ($) milestone | Dec. 31, 2016 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Current portion of deferred revenue | $ 19,665,000 | [1] |  |  | $ 31,255,000 | $ 19,665,000 | [1] | $ 31,255,000 |
Long-term portion of deferred revenue | 237,094,000 | [1] |  |  | 253,663,000 | 237,094,000 | [1] | $ 253,663,000 |
GlaxoSmithKline [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  |  |  |  | 3.00% |
Collaborative Arrangement with Ipsen [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Upfront and milestone payments |  |  |  | $ 200,000,000 |  |  |  |  |
Research and development arrangement performed for others, reimbursement for costs incurred, percent |  |  |  |  |  |  |  | 35.00% |
Reimbursements of certain clinical programs paid |  |  |  |  | 2,100,000 |  |  |  |
Current portion of deferred revenue |  |  |  |  | 19,000,000 |  |  | $ 19,000,000 |
Long-term portion of deferred revenue |  |  |  |  | $ 219,700,000 |  |  | $ 219,700,000 |
Collaborative Arrangement with Ipsen [Member] | Reclassification Adjustment [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue reclassified |  |  |  |  |  |  |  |  | $ 9,000,000
Collaborative Arrangement with Ipsen [Member] | Initial [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  |  |  |  | 2.00% |
Royalty tier |  |  |  |  |  |  |  | $ 50,000,000 |
Collaborative Arrangement with Ipsen [Member] | Second [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  |  |  |  | 12.00% |
Royalty tier |  |  |  |  |  |  |  | $ 100,000,000 |
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Royalty tier |  |  |  |  |  |  |  | $ 150,000,000 |
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  |  |  |  | 22.00% |
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  |  |  |  | 26.00% |
Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Revenue recognized, milestones | $ 10,000,000 |  |  |  |  |  |  |  |
Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member] | CABOMETYX [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Revenue recognized, milestones |  |  | $ 60,000,000 |  |  |  |  |  |
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | CABOMETYX [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Number of milestones achieved | milestone |  |  |  |  | 2 |  |  |  |
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | United Kingdom [Member] | CABOMETYX [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Revenue recognized, milestones |  |  |  |  |  | $ 10,000,000 |  |  |
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | Germany [Member] | CABOMETYX [Member] |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |
Revenue recognized, milestones |  |  |  |  | $ 10,000,000 |  |  |  |
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.

X
- Definition Payment Of Reimbursements From Collaboration Arrangement + References No definition available. + Details
Name: | exel_PaymentOfReimbursementsFromCollaborationArrangement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percent of royalty on net sale. + References No definition available. + Details
Name: | exel_PercentOfRoyaltyOnNetSale
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent + References No definition available. + Details
Name: | exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Number of Milestones Achieved + References No definition available. + Details
Name: | exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved
Namespace Prefix: | exel_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Tier + References No definition available. + Details
Name: | exel_RoyaltyTier
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments. + References No definition available. + Details
Name: | exel_UpfrontAndMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=exel_CabometyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_GB
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_DE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |